Abstract 91P
Background
Pulmonary metastasis is the most frequently occurring distant metastases of hepatocellular carcinoma (HCC). However, the indicated mechanism of pulmonary metastasis in HCC remains unclarified. Erythroid progenitor-differentiated myeloid cells (EDMCs) were reported to mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. The role of EDMCs in the metastasis of HCC and the development of pulmonary metastasis was investigated here.
Methods
The existence of EDMCs in the circulation and spleen of HCC mouse model were validated through Flow Cytometry. EDMCs were sorted using fluorescence-activated cell sorting. CFSE stained EDMCs transfer experiment were conducted to evaluated the Pulmonary metastasis promoting role in HCC mouse model. The transwell migration and invasion experiment of hepa1-6 cells (HCC cell line) cocultured with EDMCs were performed.
Results
Mouse with Pulmonary metastasis of HCC showed higher level of EDMCs in the circulation and spleen than those without Pulmonary metastasis. CFSE EDMCs stained with 5,6- carboxyfluorescein diacetate, succinimidyl ester (CFSE) were detected in the lung of HCC mouse after infusion though caudal vein and those infused mice developed more frequency of pulmonary metastasis than those without EDMCs infusion. IN the coculture experiment EDMCs promoted the migration and invasion of hepa1-6 cells.
Conclusions
EDMCs existed in the circulation of HCC mouse model. EDMCs could migrated from the circulation to the lung of HCC mice. EDMCs could facilitate migration and invasion of hepa1-6 cells migrate and invade. Thus, EDMCs can promote Pulmonary metastasis in Hepatocellular Carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wei-hang Zhu.
Funding
National Natural Science Foundation of China (81972677, 82103331), Guangdong Basic and Applied Basic Research Foundation (No. 2021A1515011022, 2022A1515010547).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09